In this study researchers want to gain more information on treatment patterns of patients treated with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the risk of blood clots via different pathways. The study will enroll adult patients suffering from coronary artery disease (narrowing or blockage of vessels that supply the heart with blood) or peripheral artery disease (narrowing or blockage of vessels that supply the legs or head with blood). The study will focus on information on when and why physicians are starting to treat patients with Xarelto in addition to ASA, treatment duration, reasons to discontinue treatment and previous therapies. The study will also look into treatment outcomes for patients being treated with a combination of Xarelto and ASA by their physicians.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Descriptive analysis of patient history of CAD
Timeframe: At baseline
Descriptive analysis of patient history of PAD
Timeframe: At baseline
Descriptive analysis of prior antithrombotic treatment
Timeframe: At baseline
Descriptive analysis of concomitant antithrombotic treatment
Timeframe: Up to 30.5 months
Descriptive analysis of prior secondary prevention therapies
Timeframe: At baseline
Descriptive analysis of concomitant secondary prevention therapies
Timeframe: Up to 30.5 months
Reason for start of rivaroxaban
Timeframe: At baseline
Decision point for start of rivaroxaban
Timeframe: At baseline
Reason for discontinuation of rivaroxaban
Timeframe: Up to 30.5 months
Planned duration of treatment with rivaroxaban
Timeframe: At baseline
Actual duration of treatment with rivaroxaban
Timeframe: Up to 30.5 months
Planned duration of treatment with acetylsalicylic acid
Timeframe: At baseline
Actual duration of treatment with acetylsalicylic acid
Timeframe: Up to 30.5 months